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Abstract
Background: Performance indicators assessing quality of diabetes care often look at single processes, e.g. whether an
HbA1c test was conducted. Adequate care, however, consists of consecutive processes which should be taken in time
(clinical pathways). We assessed quality of diabetes care by looking at single processes versus clinical pathways. In addition,
we evaluated the impact of time period definitions on this quality assessment.
Methodology: We conducted a cohort study in 2007–2008 using the GIANTT (Groningen Initiative to Analyse type 2
diabetes Treatment) database. Proportions of patients adequately managed for HbA1c, systolic blood pressure (SBP), LDL-
cholesterol (LDL-C), and albumin/creatinin ratio (ACR) were calculated for the pathway of (1) risk factor level testing, (2)
treatment intensification when indicated, (3) response to treatment evaluation. Strict and wide time periods for each step
were defined. Proportions of patients adequately managed regarding the overall pathway and single steps, using strict or
wide time periods were compared using odds ratios (OR) with 95% confidence intervals.
Findings: Of 11176 patients diagnosed with type 2 diabetes, 9439 with complete follow-up were included. The majority
received annual examination of HbA1c (86%) and SBP (86%), whereas this was 67% for LDL-C and 49% for ACR. Adequate
management regarding the three-step pathway was observed in 73%, 53%, 46%, 41% of patients for HbA1c, SBP, LDL-C,
and ACR respectively. Quality scores reduced significantly due to the second step (OR 0.43, 0.18, 0.44, 0.74), but were not
much further reduced by the third step. Timely treatment evaluation occurred in 88% for HbA1c, 87% for SBP, 83% for LDL-
C, and 76% for ACR. The overall score was not significantly changed by using strict time windows.
Conclusion: Quality estimates of glycemic, blood pressure and cholesterol management are substantially reduced when
looking at clinical pathways as compared to estimates based on commonly used simple process measures.
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Introduction
Process of care indicators are often used to assess the quality of
diabetes care [1,2]. Most of them look at specific actions in
isolation, measuring processes of care such as ‘percentages of
patients with type 2 diabetes who received an HbA1c test in a
year’. They do not reflect the overall pathway of risk factor
management as described in clinical practice guidelines, which
includes (1) a periodic test of the risk factors, (2) the initiation or
adjustment of drug treatment in patients with elevated risk factor
levels, and (3) the subsequent evaluation of response to this
treatment [3]. Estimates of quality of diabetes care show that
monitoring of risk factors may reach levels of 75–95% [4,5],
whereas treatment intensification rates in subsets of patients with
elevated risk factor levels may be as low as 15–57% [6–11]. From
these studies, it is not clear how many patients receive suboptimal
risk factor management considering all steps in succession. Nor is it
clear how much the estimate of quality is lowered by adding the
subsequent steps. Some studies have tried to quantify the overall
quality of care for risk factor management using composite scores
of commonly available process and outcome indicators [12,13],
but none of them have quantified the quality of the process of care
as a whole.
Looking at clinical pathways, one not only assesses whether
actions were taken but whether they were taken at the right time.
The timing of actions, however, is not as clearly specified in
clinical guidelines for diabetes [14–16]. Recommendations for
optimal time periods can be based on evidence and expert opinion
as well as feasibility for patients and health care organizations
[17,18]. For quality assessment, there is consensus that risk factors
should be monitored at least annually [19–22]. Regarding the
initiation or intensification of treatment in patients with elevated
risk factor levels, no specific time periods are indicated in the
guidelines. Several professionals advocate prompt action [23–25],
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on quality of diabetes care, time periods for treatment intensifi-
cation range from 14 days to 6 months [6–8,27–29]. Other studies
did not clearly specify the time periods used [9,10,30,31].
Regarding the subsequent evaluation of response to treatment,
guideline recommendations are inconsistent, and have not been
translated to process of care assessment in the field of diabetes care
[19–22,32].
The aim of our study is to assess the quality of diabetes care by
looking at the overall pathway of testing for elevated risk factor
levels, intensification of treatment, and response to treatment
evaluation, and compare this with quality as reflected by the
isolated steps of risk factor management. In addition, we will
evaluate the impact using different definitions of timeliness on this
quality assessment, and intend to propose reasonable time periods
for actions as can be derived from current clinical practice.
Methods
We conducted a longitudinal observational study using data
collected from the Groningen Initiative to Analyse Type 2 diabetes
Treatment (GIANTT) database. At the time of our study, the
GIANTT database consisted of anonymous longitudinal data
collected from medical records of more than 20,000 patients with
type 2 diabetes registered in 100 general practices in the north of
the Netherlands. The database includes all general practice
prescriptions, routine laboratory measurements and physical
examinations as documented in the electronic patient records.
Our study covers the period from the beginning of 2007 till the
end of 2008. Included were patients diagnosed with type 2
diabetes before 1
st January 2007, who were managed for diabetes
by their general practitioner, and had complete follow-up during
the study period.
Outcome measures
The outcome measures were quality of care measures derived
from the prevailing guideline recommendations at the time of our
study. This type of measures has been found face and content valid
[21,32,33]. For each of the risk factors, we calculated percentages
of (1) all patients with at least one risk factor test in 2007, (2)
patients with an elevated risk factor in 2007, and not on maximum
treatment or returning to control, who received a related
treatment intensification, (3) patients with such a treatment
intensification who received a subsequent evaluation of response
to treatment, and finally (4) patients receiving adequate care for all
three steps of this clinical pathway. Patients were considered
‘adequately managed’ when they received care as indicated by
guideline recommendations [16], including also patients with
adequate risk factor levels in whom no further steps need to be
taken, and patients on maximum treatment.
We included the following risk factors: HbA1c, systolic blood
pressure (SBP), LDL-cholesterol (LDL-C), and albumin/creatinine
ratio (ACR). We used recommendations from the prevailing
Dutch guidelines to define the actions that should be taken [16].
They recommend that these risk factors should be tested every
year in all patients with type 2 diabetes. The first elevated test
result of a risk factor in 2007 was considered as the index moment
for further actions if it did not return to control within 120 days.
Intensification of treatment is recommended for patients with
HbA1c.7%; SBP$140 mmHg; LDL-C.2.5 mmol/l; ACR
(males)$2.5 mg/mmol; ACR (females)$3.5 mg/mmol [16]. In-
tensification of treatment was defined as the start or addition of a
new drug class or a dosage increase of respectively glucose
lowering, blood pressure lowering, and lipid-lowering medication.
For elevated ACR levels, the start or dosage increase of a renin-
angiotensin-aldosterone system intervention (RAAS-i) was defined
as intensification of treatment. Evaluation of response to treatment
was defined as testing of the corresponding risk factor after
treatment intensification. For glucose lowering medication, either
testing of HbA1c or fasting blood glucose (FBG) testing was
considered as evaluation of response to treatment. Although the
primary reason for this test might not be to evaluate a treatment
response, the test results reflect the risk factor level after a change
of treatment and we assume that this is taken into account as such
by the health care provider.
Patients on maximum treatment were excluded from the total
number of patients with elevated risk factor levels when calculating
percentages of patients who received intensification of treatment.
Maximum treatment was defined according to guideline [16]. For
glucose-lowering medication, prescription of insulin was consid-
ered as having reached maximum treatment. For blood-pressure-
lowering medication, prescription of 3 or more drugs from
different classes at maximum maintenance dosage was considered
as maximum treatment. For lipid-lowering medication, prescrip-
tion of one drug at maximum dosage was considered maximum
treatment. Prescribing of either an angiotensin-converting enzyme
inhibitor or an angiotensin-II-receptor antagonist at maximum
dosage was considered maximum treatment for elevated ACR
levels. Dosage recommendations were obtained from the Dutch
Pharmacotherapy Compendium [34].
Time periods for quality assessment
We first set wide periods of 180 days for subsequent steps of
action as have been used in previous studies [6–8,28]. Next, we
defined the following time periods for treatment intensification:
prompt reaction (within 30 days), lenient reaction (within 31–120
days), and delayed reaction (within 121–180 days). The time
period of 30 days for prompt action takes into account that some
time may pass between the date of a risk factor test in the medical
record and the actual prescriber-patient contact when treatment
can be intensified. As lenient time period, we used a period of 120
days, as suggested in some studies. This takes delays until the next
regular visit due to competing demands or clinical uncertainty into
account [9,25,26]. For response to treatment evaluation, we set the
following time periods: too early reaction which could be tests
conducted for other reasons (within 42 days for HbA1c, within 14
days for SBP, and within 21 days for LDL-C), timely reaction
including a first or second test after treatment intensification (43–
120 days for HbA1c or 1–120 days for FBG, 15–120 days for SBP,
22–120 days for LDL-C, and within 365 days for ACR), and
delayed reaction (121–180 days for HbA1c/FBG, SBP, LDL-C).
The time periods for too early reactions were based on guideline
recommendations [16]. Changes in HbA1c levels should be
measured after a minimum period of 42 days, because HbA1c
reflects average glycemia over the preceding 6 weeks. No
limitations are stated for evaluation of changes in FBG level.
Changes in SBP level in response to treatment should be measured
after 2–4 weeks. LDL-C should be measured after several weeks,
which we considered to be at least 3 weeks. Regarding evaluation
of ACR in response to RAAS-i treatment there is only the
recommendation for annual audit.
Time periods derived from clinical practice
Time periods for actions can be set using evidence and expert
opinion as well as feasibility for patients and health care
organizations [17,18]. To determine reasonable time periods for
treatment intensification, we assessed feasibility by comparing our
predetermined time periods with the actual distribution of cases
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patients receiving treatment intensification over time, using 10-day
intervals after the index date. For response to treatment
evaluation, we calculated the number of patients receiving a
subsequent risk factor test over time after the treatment
intensification date, and assessed whether a change in the risk
factor levels could be observed. We used 10-day intervals for
HbA1c and SBP and 20-day intervals for LDL-C and ACR (to
gain higher numbers of eligible cases) after the date of treatment
intensification. The changes in risk factor level were calculated as
the mean difference between the risk factor level after and before
the treatment intensification. The timing for evaluation of
response to treatment was considered too early when the mean
changes in risk factor level did not yet reach a significant change.
Analysis
Descriptive analysis are presented showing percentages of
patients in each step of the clinical pathway as well adequately
managed for the overall clinical pathway using (1) wide time
periods of 180 days, and (2) strict time periods, including prompt
and lenient reactions of treatment intensification and timely
reactions of response to treatment evaluation. Using odds ratios
(OR) and 95% confidence intervals (CI) we compared the
proportions of patients who were adequately managed in the
overall three-step pathway of risk factor management (1) with
those adequately managed only regarding the first step of the
clinical pathway, and (2) with those adequately managed regarding
the first and second step. Furthermore, we compared the
proportions of patients who were adequately managed using wide
or strict time periods.
For the mean changes in risk factor levels after treatment per
10-day or 20-day interval, we present 95% confidence intervals.
To test for significant differences over time we used independent t-
tests.
Results
Overall, 11176 patients diagnosed with type 2 diabetes before
1
st of January 2007 were available for the study, of whom 9439
(84.5%) had complete follow-up until the end of 2008 and were
included in our study, whereas 1737 (15.5%) died or moved to
another region. Patients were at baseline on average 66 years of
age with a diabetes duration of almost 6 years (Table 1).
Glucose management
6878 (73%) patients were adequately managed in the three-step
pathway using the wide time periods of 180 days (Table 2). 8144
(86%) patients received at least one HbA1c test in 2007. Of the
1975 patients above target, not returning to control and not on
maximum treatment, only 759 (38%) received a treatment
intensification. Treatment intensification was prompt for 419
(55%), lenient for 262 (35%) and delayed for 78 (10%) of these
patients (Table 3). The highest peak for treatment intensification
occurred within the first 10 days (Figure 1a). Most of patients
(93%), had a next HbA1c or FBG test within 180 days after the
treatment intensification (Table 2). For 563 (88%) of these
patients, this was considered as a timely reaction (Table 3).
Evaluation of response to treatment most often occurred close to
the time of the next regular practice visit (Figure 2a). Mean
changes in HbA1c significantly improved and leveled off after 20
days since treatment intensification (p=0.04). The quality score
regarding adequate management reduced significantly due to the
second step but was not much further reduced by the third step
(Table 2). The overall score for adequate management was not
significantly higher using wide time periods (73%) in comparison
to using strict time windows (72%; OR 1.06, 95% CI 0.99–1.12).
Blood pressure management
4968 (53%) patients were adequately managed in the clinical
pathway using the wide time periods of 180 days (Table 2). 8140
(86%) patients received at least one SBP test in 2007. Of the 3864
patients above target, not returning to control and not on
maximum treatment, only 895 (23%) received a treatment
intensification. Treatment intensification was prompt for 422
(47%), lenient for 346 (39%), and delayed for 127 (14%) of these
patients (Table 3). The highest peak for treatment intensification
occurred within the first 10 days (Figure 1b). Most of patients
(77%), had a next SBP test within 180 days after the treatment
intensification (Table 2). For 514 (87%) of these patients, this was
considered as timely (Table 3). Evaluation of response to treatment
most often occurred within 30 days after index visit to health care
provider (Figure 2b). Mean changes in SBP significantly improved
and leveled off after 10 days since treatment intensification
(p=0.03). The quality score regarding adequate management
reduced significantly due to the second step, and slightly by the
third step (Table 2). The overall score for adequate management
was not significantly higher using wide time periods (53%) in
comparison to using strict time windows (53%; OR 1.00, 95% CI
0.94–1.06).
LDL-cholesterol management
4383 (46%) patients were adequately managed in the clinical
pathway using the wide time periods of 180 days (Table 2). 6264
(67%) patients received at least one LDL-C test in 2007. Of the
Table 1. Patient characteristics at baseline.
Number of patients with observation (%) Mean ± standard deviation
Age (years) 9439 66612.1
Male gender 4493 (47.6)
Diabetes duration (years) 9439 5.665.6
HbA1c (%) 8144 6.861.0
Systolic blood pressure (mmHg) 8140 142.8620.5
LDL-cholesterol (mmol/l) 6264 2.460.9
Total cholesterol (mmol/l) 6424 4.461.1
Albumin/creatinin ratio (mg/mmol) 4604 4.0615.3
doi:10.1371/journal.pone.0024278.t001
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maximum treatment, only 355 (17%) received a treatment
intensification. Treatment intensification was prompt for 205
(58%), lenient for 103 (29%), and delayed for 47 (13%) of these
patients (Table 3). The highest peak for treatment intensification
occurred within the first 10 days (Figure 1c). More than half of
patients (52%), had a next LDL-C test within 180 days after
treatment intensification (Table 2). For 132 (83%) of these
patients, this was considered as timely (Table 3). Evaluation of
response to treatment most often occurred close to time of the next
Table 2. Percentages of patients who received recommended care within wide time periods of 180 days.
HbA1c SBP LDL-C ACR
n=9439 n=9439 n=9439 n=9439
Adequately managed in the clinical pathway
as indicated within time periods of 180 days
6878 (73%) 4968 (53%) 4383 (46%) 3905 (41%)
Step 1 Risk factor testing in whole population
Risk factor test in 2007 8144 (86%) 8140 (86%) 6264 (67%) 4604 (49%)
- elevated level 2556 (31%) 4713 (58%) 2332 (37%) 1165 (25%)
- return to control within 120 days 339 (13%) 776 (16%) 117 (5%) 187 (16%)
- maximum treatment 242 (9%) 73 (2%) 150 (6%) 227 (19%)
Odds Ratio (95%CI) of adequate management step 1 versus
all 3 steps
0.43 (0.35–0.50) 0.18 (0.11–0.25) 0.44 (0.38–0.50) 0.74 (0.68–0.80)
Step 2 Treatment intensification in patients with elevated risk factor level who are not on maximum treatment
n=1975 n=3864 n=2065 n=751
Intensification of treatment within 180 days 759 (38%) 895 (23%) 355 (17%) 136 (18%)
Odds Ratio (95%CI) of adequate management of steps 1 and 2
versus all 3 steps
0.97 (0.91–1.04) 0.92 (0.86–0.97) 0.93 (0.87–0.99) 0.96 (0.91–1.02)
Step 3 Evaluation of response to treatment in patients who received intensification of treatment
n=759 n=895 n=355 n=136
Evaluation of response to treatment within 180 days 709 (93%)* 692 (77%) 184 (52%) 52 (38%)
*First test of HbA1c or fasting blood glucose observed after intensification of treatment.
doi:10.1371/journal.pone.0024278.t002
Table 3. Percentages of patients who received care within predefined time periods.
HbA1c SBP LDL-C ACR
n=9439 n=9439 n=9439 n=9439
Adequately managed in the clinical pathway within
strict time periods*
6776 (72%) 4969 (53%) 4479 (47%) 3989 (42%)
Step 1 Risk factor testing in whole population
Risk factor test in 2007 8144 (86%) 8140 (86%) 6264 (67%) 4604 (49%)
- elevated level 2556 (31%) 4713 (58%) 2332 (37%) 1165 (25%)
- return to control within 120 days 339 (13%) 776 (16%) 117 (5%) 187 (16%)
- maximum treatment 242 (9%) 73 (2%) 150 (6%) 227 (19%)
Step 2 Treatment intensification in patients with elevated risk factor level who are not on maximum treatment
n=759 n=895 n=355 n=136
- prompt reaction (within 30 days) 419 (55%) 422 (47%) 205 (58%) 56 (42%)
- lenient reaction (within 31–120 days) 262 (35%) 346 (39%) 103 (29%) 59 (43%)
- delayed reaction (within 121–180 days) 78 (10%) 127 (14%) 47 (13%) 21 (15%)
Step 3 Evaluation of response to treatment in patients who received prompt or lenient reaction of treatment intensification
n=637 n=589 n=160 n=87
- too early reaction** 39 (6%) 53 (9%) 2 (1%) -
- timely reaction (within 120 days without too early) 563 (88%) 514 (87%) 132 (83%) 87 (76%)
+
- delayed reaction (within 121–180 days) 35 (6%) 22 (4%) 26 (16%) -
*Time periods of prompt and lenient reactions of treatment intensification and timely reaction of response to treatment evaluation.
**Within 42 days for HbA1c, no restriction for FBG, within 14 days for SBP, and within 21 days for LDL-cholesterol, no recommendations for too early ACR.
+Within 1 year period.
doi:10.1371/journal.pone.0024278.t003
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a trend to improvement and leveled off after 20 days since
treatment intensification (p=0.06). The quality score regarding
adequate management reduced significantly due to the second
step, and slightly by the third step (Table 2). The overall score for
adequate management was not significantly different using wide
time periods (46%) in comparison to using strict time windows
(47%; OR 0.96, 95% CI 0.90–1.02).
Albuminuria management
3905 (41%) patients were adequately managed in the clinical
pathway using the time periods of 180 days (Table 2). 4604 (49%)
patients received at least one ACR test in 2007. Of the 751
patients above target, not returning to control and not on
maximum treatment, only 136 (18%) received a treatment
intensification. Treatment intensification was prompt for 56
(42%), lenient for 59 (43%) and delayed for 21 (15%) of these
patients (Table 3). The highest peak for treatment intensification
occurred within the first 10 days (Figure 1d). 52 (38%) patients had
a next ACR test within 180 days after treatment intensification
(Table 2) and 87 (76%) patients had a next ACR test within a year,
which was considered as timely (Table 3). Mean changes in ACR
did not show clear improvement on the timeline within 100 days
(p=0.98). The quality score regarding adequate management
reduced significantly due to the second step but was not much
further reduced by the third step (Table 2). The overall score for
adequate management was not significantly different using wide
time periods (41%) in comparison to using recommended strict
time windows (42%; OR 0.96, 95% CI 0.91–1.02).
Discussion
Quality of risk factor management in diabetes looking at the
three-step process of care pathway showed that up to 59% of the
patients may receive less care than recommended according to the
guidelines. Specifically, quality estimates of glycemic, blood
pressure and cholesterol management were substantially reduced
when looking at clinical pathways as compared to estimates based
on commonly used simple process measures. The assessed quality
was higher for glycemic management than for blood pressure or
cholesterol and especially albuminuria management, regardless of
the time periods used for defining the quality. Suboptimal quality
seems mostly driven by lack of treatment intensification for all risk
factors, and by lack of risk factor testing for cholesterol and
albuminuria management. Although treatment intensifications
often occurred within 30 days, taking into account actions until the
next regular practice visit almost doubled the estimated quality of
treatment intensification for patients with elevated risk factor
levels. The percentages of patients who received the recommended
care did not significantly increase when further extending time
periods for quality assessment up to 180 days.
At each step of the clinical pathway patients received less care
than recommended. Regarding risk factor testing, in particular
fewerpatients received atleast one test of LDL-Cand ACRwithina
year. Previous studies also showed room for improvement regarding
quality of testing for cholesterol and albuminuria in diabetes
patients [8,35,36]. This may be explained by the fact that routine
testing of cholesterol and albuminuria is recommended once a year
whereas this is half-yearly or quarterly for glycemia and blood
pressure. Tests conducted once yearly have a higher chance of
Figure 1. Timing of treatment intensification after risk factor test (number of patients per 10 days period).
doi:10.1371/journal.pone.0024278.g001
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would support the choice made in the British Quality and Outcome
Frameworksystem touseperiods of 15monthsinstead of 12months
for quality assessment of risk factor testing [19].
Regarding treatment intensification among patients with
elevated risk factors level, the low rates observed are consistent
with previous studies in the Netherlands [7,8,11] and in other
health care settings [31,37–40]. Patients received more treatment
intensification in response to elevated levels of HbA1c than SBP,
LDL-C and ACR, which is also in line with previous studies
[7,11,41]. Allowing for treatment intensification on the next
regular visit, i.e. within 120 days in The Netherlands, covers more
than 85% of the intensifications occurring after elevated levels.
This could be considered as a reasonable time period based on
current clinical practice [17,18]. In general, however, the
intensification rates remained low. This shows that delay in action
is not the most important factor for the observed low rates. Other
explanations have been suggested, such as uncertainty regarding
elevated risk factor levels, disagreement with guideline recom-
mendations, the inability to intensify treatment in some patients,
and refusal by patients [9,42,43]. Previous studies in our study
population showed, however, that factors such as medication
burden and medication non-adherence were not associated with
lower treatment intensification rates [11,44]. We excluded patients
who were already on maximum treatment or returned to control,
but there may still be some patients who did not tolerate or wanted
to receive a treatment intensification. This would result in
underestimates of the quality of care.
The third step of the clinical pathway, response to treatment
evaluation, has not been studied before as part of quality
assessment in diabetes management. Our findings demonstrated
that, similar to risk factor testing in general, response to treatment
evaluation is conducted more often for HbA1c and SBP
management than for LDL-C and ACR management. This
evaluation is also liable to setting of different time periods.
Evaluation of treatment can be conducted not only too late but
also too early. Too early evaluation can satisfy the definition of a
quality indicator but be irrelevant from a clinical point of view.
Few patients received an HbA1c test within six weeks after
intensification of glucose-lowering treatment, which is too early
according to Dutch guideline [16]. Other guidelines, such as from
the American Diabetes Association, consider longer periods of 2–3
months over which HbA1c reflects changes [14]. In turn, we
observed improvements in mean HbA1c levels already after a
period of 20 days, which could indicate that for clinical practice
assessment a minimum period of 3 weeks could be adequate for
response to glucose-lowering treatment evaluation. For evaluating
response to antihypertensive treatment, guidelines recommend to
measure the SBP after 2–4 weeks. This corresponds with
improvements in mean SBP levels we observed after 10 days,
indicating that a minimum period of 2 weeks could be used as
adequate for response to antihypertensive treatment evaluation.
For lipid-lowering treatment, the Dutch guideline states that an
evaluation should take place after several weeks, which we defined
as 3 weeks [16]. The American guideline recommends a minimal
period of 6 weeks for response to treatment evaluation [45]. Our
Figure 2. Timing of response to treatment evaluation after treatment intensification (number of patients per 10- or 20-days period
in bars, and 10- or 20-day mean values of changes in risk factor levels in line graphs).
doi:10.1371/journal.pone.0024278.g002
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to reflect adequate response to lipid-lowering treatment evalua-
tion. Regarding evaluation of response to RAAS-i treatment in
case of albuminuria, it has only been stated that repeated testing is
reasonable [46], but guidelines recommend only annual routine
testing of ACR [14,16]. In our study, no firm conclusions can be
drawn due to the small numbers of patients with recurrent ACR
tests.
The strength of our study is that it was conducted using a non-
restricted population of primary care patients with type 2 diabetes
using data from medical records. It reflects quality of diabetes care
in the northern part of the Netherlands which may differ from
other countries. It is limited to process of care assessment, whereas
quality of care can also be assessed by including (intermediate)
outcome measures. This is, for example, the case in the British
Quality and Outcome Framework [19]. The chosen definitions of
adequate care are consistent with other international and national
guidelines for type 2 diabetes [14,15,47–49]. Although one might
question whether treatment intensification is needed or wanted in
all patients above the defined target values, especially given recent
findings of published clinical trials [50,51], our study reflects
quality of care as measured according to recommendations in
prevailing diabetes guidelines at the time of our study. The quality
measures we used were derived from these guideline, and as such
can be considered content valid. There is, however, limited
evidence for their predictive validity regarding patient outcomes
[52]. We considered changes in treatment after one elevated level
as adequate, since in this type of longitudinal observational study
this can already be a recurrent elevated risk factor measurement.
We based our proposed time periods on a combination of
guideline recommendations and feasibility in daily practice.
Ultimately, definitions of the optimal time periods should be
based on their impact on health outcomes. The effect of the time
period definitions on quality assessment is likely to depend on
reimbursement, and local or national organization and agreements
for regular or standard care. In the Netherlands, as in many other
countries, diabetes patients usually have a regular visit with their
health care provider every three months. Our predefined time
periods may be less applicable for settings where this is not the
case. To assess too early response to treatment evaluation, we
chose 10-day and 20-day intervals to have sufficient numbers of
patients on the one hand, and clinically meaningful time intervals
on the other. For albuminuria, however, this resulted in small
numbers of patients per interval and unreliable outcome estimates.
Study data were obtained from electronic patient records of
general practices using validated procedures [53]. Such patient
records provide detailed clinical information, however, they may
be incomplete and contain misclassifications. Especially, tests and
drugs prescribed by specialists in the hospital can be missed. Since
we included only patients who are primarily managed by their
general practitioner, this will be uncommon for our study
population. Furthermore, dates of tests in patient records may
be imprecise, either reflecting the date when the test was
performed or the date when the result was received in the
practice. This was taken into account by defining prompt reaction
to testing as any action within a period of 30 days.
In conclusion, looking at the overall pathway of risk factor
management in diabetes significantly lowers estimates of quality as
compared to the assessment based on commonly used simple
process measures. Our study showed that this reduction is mostly
driven by lack of treatment intensification for all risk factors. Based
on our findings from clinical practice, a period of 12 months may
be too short for assessing annual testing of risk factors such as
cholesterol and albuminuria. For assessing intensification of
treatment and response to treatment, it seems reasonable to allow
for the next routine diabetes visit. Extension of the time periods for
quality assessment up to half a year did not significantly influence
the quality estimates.
Author Contributions
Development of conception and formulating of a research question: GS PD
DdZ FMH-R. Acquisition of data: PD. Analysis and interpretation of data:
GS PD. Drafting of the article: GS. Critical revising: GS PD DdZ FMH-R.
Final approval: GS PD DdZ FMH-R.
References
1. Brook RH, McGlynn EA, Shekelle PG (2000) Defining and measuring quality of
care: A perspective from US researchers. Int J Qual Health Care 12(4): 281–295.
2. Donabedian A (1988) The quality of care. how can it be assessed? JAMA
260(12): 1743–1748.
3. Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, et al. (1997) Evidence-based disease
management. JAMA 278(20): 1687–1692.
4. Nicolucci A, Rossi MC, Arcangeli A, Cimino A, de Bigontina G, et al. (2010)
Four-year impact of a continuous quality improvement effort implemented by a
network of diabetes outpatient clinics: The AMD-annals initiative. Diabet Med
27(9): 1041–1048.
5. Trivedi AN, Grebla RC, Wright SM, Washington DL (2011) Despite improved
quality of care in the veterans affairs health system, racial disparity persists for
important clinical outcomes. Health Aff (Millwood) 30(4): 707–715.
6. Rodondi N, Peng T, Karter AJ, Bauer DC, Vittinghoff E, et al. (2006) Therapy
modifications in response to poorly controlled hypertension, dyslipidemia, and
diabetes mellitus. Ann Intern Med 144(7): 475–484.
7. van Bruggen R, Gorter K, Stolk R, Klungel O, Rutten G (2009) Clinical inertia
in general practice: Widespread and related to the outcome of diabetes care.
Fam Pract 26(6): 428–436.
8. Voorham J, Haaijer-Ruskamp FM, van der Meer K, de Zeeuw D,
Wolffenbuttel BH, et al. (2010) Identifying targets to improve treatment in type
2 diabetes; the groningen initiative to aNalyse type 2 diabetes treatment
(GIANTT) observational study. Pharmacoepidemiol Drug Saf 19(10):
1078–1086.
9. Kerr EA, Zikmund-Fisher BJ, Klamerus ML, Subramanian U, Hogan MM,
et al. (2008) The role of clinical uncertainty in treatment decisions for diabetic
patients with uncontrolled blood pressure. Ann Intern Med 148(10): 717–
727.
10. Sperl-Hillen JM, O’Connor PJ (2005) Factors driving diabetes care improve-
ment in a large medical group: Ten years of progress. Am J Manag Care 11(5
Suppl): S177–85.
11. Voorham J, Haaijer-Ruskamp FM, Stolk RP, Wolffenbuttel BH, Denig P, et al.
(2008) Influence of elevated cardiometabolic risk factor levels on treatment
changes in type 2 diabetes. Diabetes Care 31(3): 501–503.
12. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, et al. (2008)
Quality of diabetes care predicts the development of cardiovascular events:
Results of the QuED study. Nutr Metab Cardiovasc Dis 18(1): 57–65.
13. Gorter K, van Bruggen R, Stolk R, Zuithoff P, Verhoeven R, et al. (2008)
Overall quality of diabetes care in a defined geographic region: Different sides of
the same story. Br J Gen Pract 58(550): 339–345.
14. American Diabetes Association (2011) Standards of medical care in diabetes–
2011. Diabetes Care 34 Suppl 1: S11–61.
15. IDF Clinical Guidelines Task Force (2006) Global guideline for type 2 diabetes:
Recommendations for standard, comprehensive, and minimal care. Diabet Med
23(6): 579–593.
16. Rutten GE, De Grauw WJ, Nijpels G, Goudswaard AN, Uitewaal P, et al. (2006)
[NHG-standaard diabetes mellitus type 2 (second revision)]. Huisarts Wet 49(3):
137–152.
17. Shekelle PG, Woolf SH, Eccles M, Grimshaw J (1999) Clinical guidelines:
Developing guidelines. BMJ 318(7183): 593–596.
18. Schunemann HJ, Fretheim A, Oxman AD, WHO Advisory Committee on
Health Research (2006) Improving the use of research evidence in guideline
development: 1. guidelines for guidelines. Health Res Policy Syst 4: 13.
19. British Medical Association (BMA) and NHS Employers (2009) Quality and
outcomes framework guidance for GMS contract 2009/10. : 162.
20. National Committee for Quality Assurance (NCQA) (2010) HEDISH 2011:
Healthcare effectiveness data and information set. vol. 1, narrative. : various.
21. Nicolucci A, Greenfield S, Mattke S (2006) Selecting indicators for the quality of
diabetes care at the health systems level in OECD countries. Int J Qual Health
Care 18 Suppl 1: 26–30.
22. Office of Quality Performance (2009) FY 2009, Q2 technical manual for the
VHA performance measurement system. : various.
Adequacy and Timeliness of Diabetes Care
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e2427823. Brown JB, Nichols GA, Perry A (2004) The burden of treatment failure in type 2
diabetes. Diabetes Care 27(7): 1535–1540.
24. Kuritzky L, Epstein BJ, Lavernia F (2010) How to obtain appropriate type 2
diabetes control in the first 180 days of treatment initiation. Postgrad Med
122(3): 33–42.
25. Phillips LS, Twombly JG (2008) It’s time to overcome clinical inertia. Ann
Intern Med 148(10): 783–785.
26. Turner BJ, Hollenbeak CS, Weiner M, Ten Have T, Tang SS (2008) Effect of
unrelated comorbid conditions on hypertension management. Ann Intern Med
148(8): 578–586.
27. Berlowitz DR, Ash AS, Glickman M, Friedman RH, Pogach LM, et al. (2005)
Developing a quality measure for clinical inertia in diabetes care. Health Serv
Res 40(6 Pt 1): 1836–1853.
28. Selby JV, Uratsu CS, Fireman B, Schmittdiel JA, Peng T, et al. (2009)
Treatment intensification and risk factor control: Toward more clinically
relevant quality measures. Med Care 47(4): 395–402.
29. Voorham J, Haaijer-Ruskamp FM, Wolffenbuttel BH, Stolk RP, Denig P, et al.
(2011) Medication adherence affects treatment modifications in patients with
type 2 diabetes. Clin Ther 33(1): 121–134.
30. Grant RW, Cagliero E, Dubey AK, Gildesgame C, Chueh HC, et al. (2004)
Clinical inertia in the management of type 2 diabetes metabolic risk factors.
Diabet Med 21(2): 150–155.
31. Ziemer DC, Miller CD, Rhee MK, Doyle JP, Watkins C, Jr., et al. (2005)
Clinical inertia contributes to poor diabetes control in a primary care setting.
Diabetes Educ 31(4): 564–571.
32. Wens J, Dirven K, Mathieu C, Paulus D, Van Royen P, et al. (2007) Quality
indicators for type-2 diabetes care in practice guidelines: An example from six
european countries. Prim Care Diabetes 1(1): 17–23.
33. Martirosyan L, Voorham J, Haaijer-Ruskamp FM, Braspenning J,
Wolffenbuttel BH, et al. (2010) A systematic literature review: Prescribing
indicatorsrelated to type 2 diabetes mellitus and cardiovascular risk management.
Pharmacoepidemiol Drug Saf 19(4): 319–334.
34. Dutch Health Care Insurance Board (Commissie Farmaceutische Hulp van het
College van Zorgverzekeringen) (2009) Dutch pharmacotherapy compendium (Kompas),
2009.
35. Aakre KM, Thue G, Subramaniam-Haavik S, Cooper J, Bukve T, et al. (2010)
Diagnosing microalbuminuria and consequences for the drug treatment of
patients with type 2 diabetes: A european survey in primary care. Diabetes Res
Clin Pract 89(2): 103–109.
36. Massing MW, Henley NS, Carter-Edwards L, Schenck AP, Simpson RJ, Jr.
(2003) Lipid testing among patients with diabetes who receive diabetes care from
primary care physicians. Diabetes Care 26(5): 1369–1373.
37. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, et al. (2001) Clinical
inertia. Ann Intern Med 135(9): 825–834.
38. Triplitt C (2010) Improving treatment success rates for type 2 diabetes:
Recommendations for a changing environment. Am J Manag Care 16(7 Suppl):
S195–200.
39. Zafar A, Davies M, Azhar A, Khunti K (2010) Clinical inertia in management of
T2DM. Prim Care Diabetes 4(4): 203–207.
40. Charpentier G, Genes N, Vaur L, Amar J, Clerson P, et al. (2003) Control of
diabetes and cardiovascular risk factors in patients with type 2 diabetes: A
nationwide french survey. Diabetes Metab 29(2 Pt 1): 152–158.
41. Greving JP, Denig P, de Zeeuw D, Bilo HJ, Haaijer-Ruskamp FM (2007) Trends
in hyperlipidemia and hypertension management in type 2 diabetes patients
from 1998–2004: A longitudinal observational study. Cardiovasc Diabetol 6: 25.
42. AB E, Denig P, van Vliet T, Dekker J (2009) Reasons of general practitioners for
not prescribing lipid-lowering medication to patients with diabetes: A qualitative
study. BMC Family Practice 10(1): 24.
43. Viera AJ, Schmid D, Bostrom S, Yow A, Lawrence W, et al. (2010) Level of
blood pressure above goal and clinical inertia in a medicaid population. J Am
Soc Hypertens 4(5): 244–254.
44. Voorham J, Haaijer-Ruskamp FM, Wolffenbuttel BH, Stolk RP, Denig P, et al.
(2010) Cardiometabolic treatment decisions in patients with type 2 diabetes: The
role of repeated measurements and medication burden. Qual Saf Health Care
19(5): 411–415.
45. National Cholesterol Education Program. Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (2001 (Updated
2004)) Third report of the expert panel on detection, evaluation, and treatment
of high blood cholesterol in adults (adult treatment panel III).
46. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, et al. (2002)
Guidelines and recommendations for laboratory analysis in the diagnosis and
management of diabetes mellitus. Clin Chem 48(3): 436–472.
47. Colagiuri R, Girgis S, Gomez M, Walker K, Colagiuri S, O’Dea K (2009)
National evidence based guideline for the primary prevention of type 2 diabetes.
Available: www.diabetesaustralia.com.au/For-Health-Professionals/Diabetes-
National-Guidelines/Accessed 16 June 2011.
48. National Collaborating Centre for Chronic Conditions (2008) Type 2 diabetes:
National clinical guideline for management in primary and secondary care
(update). Available: http://guidance.nice.org.uk/CG66 Accessed 16 June 2011.
49. Canadian Diabetes Association (2008) Clinical practice guidelines for the
prevention and management of diabetes in canada. Can J Diab 32(Supplement
1).
50. Hoogwerf BJ, Action to Control Cardiovascular Risk in, Diabetes Study Group
(2008) Does intensive therapy of type 2 diabetes help or harm? Seeking accord
on ACCORD. Cleve Clin J Med 75(10): 729–737.
51. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B,
et al. (2008) Intensive blood glucose control and vascular outcomes in patients
with type 2 diabetes. N Engl J Med 358(24): 2560–2572.
52. Sidorenkov G, Haaijer-Ruskamp FM, de Zeeuw D, Bilo H, Denig P (2011)
Review: Relation between quality-of-care indicators for diabetes and patient
outcomes: A systematic literature review. Med Care Res Rev 68(3): 263–289.
53. Voorham J, Denig P (2007) Computerized extraction of information on the
quality of diabetes care from free text in electronic patient records of general
practitioners. J Am Med Inform Assoc 14(3): 349–354.
Adequacy and Timeliness of Diabetes Care
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e24278